Clinical Challenge and Perioperative Liposomal Bupivacaine

Postcraniotomy pain presents a substantial hurdle for neurosurgeons and neuroanesthesiologists. Untreated postoperative pain frequently triggers sympathetic surges, which increase blood pressure and intracranial pressure. Consequently, severe pain elevates the danger of intracranial hemorrhage and cerebral edema. Conversely, excessive opioid reliance risks sedation, hypercapnia, and impaired neurological assessment. Clinicians actively pursue opioid-sparing regional techniques to optimize patient recovery. In this surgical setting, perioperative liposomal bupivacaine has emerged as a promising extended-release local anesthetic. Surgical teams typically employ scalp infiltration or scalp nerve blocks to alleviate acute somatic pain. However, standard local anesthetics like bupivacaine provide analgesia for only six to eight hours. Because severe postcraniotomy pain persists across the first forty-eight hours, standard agents leave patients vulnerable. Perioperative liposomal bupivacaine addresses this challenge through prolonged drug release lasting up to ninety-six hours. By encapsulating bupivacaine within multivesicular liposomes, the formulation provides sustained tissue analgesia. Nonetheless, clinical evidence validating its efficacy in neurosurgery has remained limited. A recent systematic review scrutinized the available clinical literature to evaluate whether this formulation genuinely enhances neurosurgical outcomes.

Pharmacological Profile and Sustained-Release Mechanisms

Understanding the pharmacology of liposomal bupivacaine clarifies its clinical intent. The proprietary multivesicular DepoFoam technology encapsulates aqueous bupivacaine inside synthetic lipid chambers. As these microscopic vesicles gradually degrade, they release free bupivacaine slowly into local tissues. Consequently, the drug delivers prolonged membrane stabilization without triggering immediate systemic toxic concentrations. Traditional local anesthetics clear rapidly from the highly vascular scalp tissue, which significantly limits their duration. In contrast, liposomal formulations maintain localized analgesic concentrations over multiple postoperative days. This continuous delivery theoretically blunts the secondary inflammatory pain cascade triggered by scalp incisions, muscle reflection, and skull-pin application. Furthermore, local infiltration targets pericranial sensory nerves, including the supraorbital, supratrochlear, and occipital branches. Because postcraniotomy pain arises predominantly from superficial myofascial disruption rather than brain parenchyma, targeted infiltration offers rational analgesia. However, clinicians must respect strict handling standards. Improper mixing with non-bupivacaine local anesthetics disrupts the lipid matrix, causing rapid bupivacaine dumping and increasing toxicity risks. Therefore, surgical teams must follow precise dilution and administration protocols to protect patient safety.

Adult Craniotomy Outcomes and Cost Implications

The systematic review evaluated adult outcomes from a single-center retrospective study of aneurysm-clipping craniotomy. Researchers compared adult patients receiving liposomal bupivacaine against those receiving conventional local anesthetic infiltration. Interestingly, patients in the liposomal bupivacaine cohort experienced lower mean postoperative pain scores and reduced opioid consumption. Additionally, the intervention group demonstrated a shorter duration of hospital stay. However, statistical analysis revealed that none of these clinical differences reached statistical significance. The lack of statistical divergence likely stemmed from small sample sizes and retrospective confounding. Moreover, the study highlighted a striking difference regarding total hospital expenditures. Patients receiving liposomal bupivacaine accumulated significantly higher total analgesic costs than those receiving standard care. In adult neurovascular surgery, maintaining hemodynamic stability is vital to prevent aneurysm rupture or postoperative ischemia. While prolonged analgesia provides theoretical advantages, the present adult data fail to demonstrate clinical superiority over inexpensive standard anesthetics. Therefore, clinicians cannot currently justify routine implementation in adult craniotomy based solely on clinical efficacy. Substantial procurement costs further limit adoption in modern healthcare institutions.

Pediatric Cranial Surgery and Opioid-Sparing Evidence

In contrast to adult data, the systematic review identified three pediatric cohorts. These studies evaluated liposomal bupivacaine in children undergoing cranial vault remodelling or Chiari decompression surgery. Pediatric patients frequently suffer from extensive suboccipital and calvarial dissection, which causes severe early postoperative distress. Notably, retrospective data showed associations between liposomal bupivacaine and lower opioid consumption. In one Chiari decompression cohort, treated children required significantly fewer opioids during the critical first twenty-four hours. Similarly, in a cranial vault remodelling cohort, pediatric patients demonstrated decreased opioid requirements across the first three postoperative days. These findings suggest that extended-release local anesthesia may successfully blunt prolonged myofascial pain in pediatric reconstructive cases. Nevertheless, findings across the pediatric studies remained inconsistent regarding secondary endpoints. Several cohorts showed variable effects on subjective pain scores, likely due to behavioral distress and age-related assessment challenges. Furthermore, liposomal bupivacaine failed to produce uniform reductions in intensive care unit or total hospital length of stay. Consequently, while pediatric data appear promising, current retrospective evidence offers low certainty.

Current Practice Recommendations and Future Trial Priorities

Based on the current totality of evidence, experts cannot endorse routine perioperative liposomal bupivacaine for cranial procedures. The available medical literature comprises only four small retrospective single-center investigations involving 184 total patients. This small evidence base carries a high risk of selection bias and unmeasured clinical confounders. Therefore, neurosurgical departments should maintain established multimodal pain protocols using conventional local anesthetics and systemic non-opioid analgesics. To resolve persistent clinical uncertainties, researchers must conduct robust prospective randomized controlled trials. These future trials should enroll adequately powered cohorts undergoing standardized procedures, such as supratentorial craniotomy, posterior fossa decompression, or craniosynostosis repair. Additionally, trial designs must directly compare liposomal bupivacaine against active standard comparators, such as bupivacaine plus dexamethasone or ropivacaine scalp blocks. Investigators must measure patient-centered outcomes, including numerical pain scores, rescue morphine milligram equivalents, and chronic postsurgical headache incidence. Comprehensive cost-utility analyses must also accompany clinical assessments to establish value in modern surgical care. Until high-certainty randomized evidence demonstrates tangible clinical improvements, liposomal bupivacaine should remain an experimental adjunct rather than standard neurosurgical practice.

What are the primary advantages of liposomal bupivacaine over standard local anesthetics?

Liposomal bupivacaine encapsulates standard bupivacaine inside multivesicular lipid chambers, which enables controlled drug release over ninety-six hours. In contrast, conventional bupivacaine typically provides analgesia for only six to eight hours. By prolonging local tissue anesthesia, this formulation aims to decrease peak postoperative pain scores, reduce cumulative systemic opioid requirements, and prevent opioid-related adverse reactions such as nausea, sedation, and hypoventilation in surgical patients.

Why is routine use of liposomal bupivacaine not yet recommended in cranial neurosurgery?

Current scientific evidence remains sparse and of very low certainty. The systematic review identified only four retrospective studies comprising 184 patients. In adult aneurysm surgery, the drug produced no statistically significant reductions in pain scores, opioid usage, or length of hospital stay, while significantly increasing pharmacy costs. Although pediatric studies showed early opioid reductions, findings were inconsistent across procedures. Therefore, guidelines require high-quality randomized controlled trials before recommending routine implementation.

How do pediatric neurosurgery patients respond to perioperative liposomal bupivacaine infiltration?

Small retrospective pediatric cohorts undergoing Chiari malformation decompression and cranial vault remodelling experienced noticeable early benefits. Specifically, children receiving liposomal bupivacaine demonstrated reduced opioid consumption during the first twenty-four to seventy-two postoperative hours. However, improvements in subjective pain scores and total hospital length of stay varied widely across cohorts. Because available studies relied on retrospective charts with small cohorts, clinicians cannot draw definitive conclusions without prospective pediatric clinical trials.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Healthcare professionals should exercise their clinical judgment and consult relevant clinical guidelines, institutional protocols, and official product labeling when making treatment decisions. The authors and publishers assume no liability for any injury or damage resulting from the use of this information. Refer to the latest local and national guidelines for clinical practice.

References

1. Jamileh E et al. Perioperative Liposomal Bupivacaine for Postoperative Pain Control in Cranial Neurosurgery: A Systematic Review. Anesthesiol Res Pract. 2026 undefined undefined. doi: 10.1155/anrp/6822812. PMID: 42978970.


2. Satıcı MH, Tutar MS, Kozanhan B, Tire Y, Çöven I, Altay N. Effects of SCALP block on postoperative analgesia in craniotomy surgery: a prospective, randomized controlled, double-blind study. Med J Bakirkoy. 2025;21:76-82.


3. Suriyandi F, Wibowo CR. A comprehensive systematic review of the effectiveness of regional scalp block in craniotomy on postoperative pain and intraoperative haemodynamic response. J Clin Anesth Pain Med. 2026;7(2):112-120.